These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 22898224)

  • 1. A multicenter study of clinical and laboratory findings of palindromic rheumatism in Iran.
    Khabbazi A; Hajialiloo M; Kolahi S; Soroosh M; Esalatmanesh K; Sharif S
    Int J Rheum Dis; 2012 Aug; 15(4):427-30. PubMed ID: 22898224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for the development of rheumatoid arthritis and other connective tissue diseases in patients with palindromic rheumatism.
    Gonzalez-Lopez L; Gamez-Nava JI; Jhangri GS; Ramos-Remus C; Russell AS; Suarez-Almazor ME
    J Rheumatol; 1999 Mar; 26(3):540-5. PubMed ID: 10090159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factor-positive patients.
    García-Berrocal B; González C; Pérez M; Navajo JA; Moreta I; Dávila C; González-Buitrago JM
    Clin Chim Acta; 2005 Apr; 354(1-2):123-30. PubMed ID: 15748608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor.
    Yamane T; Hashiramoto A; Tanaka Y; Tsumiyama K; Miura Y; Shiozawa K; Chihara K; Shiozawa S
    J Rheumatol; 2008 Mar; 35(3):414-20. PubMed ID: 18203327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
    Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
    Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factor-negative suspected rheumatoid arthritis: is it worthwhile to order the test?
    Panchagnula R; Rajiv SR; Prakash J; Chandrashekara S; Suresh KP
    J Clin Rheumatol; 2006 Aug; 12(4):172-5. PubMed ID: 16891919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis?
    Girelli F; Foschi FG; Bedeschi E; Calderoni V; Stefanini GF; Martinelli MG
    Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):127-30. PubMed ID: 15180353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy.
    de Man YA; Bakker-Jonges LE; Goorbergh CM; Tillemans SP; Hooijkaas H; Hazes JM; Dolhain RJ
    Ann Rheum Dis; 2010 Feb; 69(2):420-3. PubMed ID: 19282308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis.
    Russell AS; Devani A; Maksymowych WP
    J Rheumatol; 2006 Jul; 33(7):1240-2. PubMed ID: 16724377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of anti cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity.
    Sockalingam S; Khuan CS; Sthaneshwar P
    Int J Rheum Dis; 2009 Sep; 12(3):211-5. PubMed ID: 20374348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
    Us D; Gülmez D; Hasçelik G
    Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed during the first year of followup in recent-onset arthritis? A longitudinal study.
    Mjaavatten MD; van der Heijde DM; Uhlig T; Haugen AJ; Nygaard H; Bjørneboe O; Kvien TK
    J Rheumatol; 2011 Nov; 38(11):2336-41. PubMed ID: 21965645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study.
    Sanmartí R; Cabrera-Villalba S; Gómez-Puerta JA; Ruiz-Esquide V; Hernández MV; Salvador G; Ramirez J; Viñas O; Cañete JD
    J Rheumatol; 2012 Oct; 39(10):1929-33. PubMed ID: 22859345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.